Global Non-invasive DNA Prenatal Testing Market Growth (Status and Outlook) 2024-2030

Global Non-invasive DNA Prenatal Testing Market Growth (Status and Outlook) 2024-2030

Non-invasive prenatal DNA testing is a new generation of prenatal testing technology that uses next-generation high-throughput sequencing to detect fetal chromosomal abnormalities.

The global Non-invasive DNA Prenatal Testing market size is projected to grow from US$ 4600.7 million in 2023 to US$ 10460 million in 2030; it is expected to grow at a CAGR of 12.4% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Non-invasive DNA Prenatal Testing Industry Forecast” looks at past sales and reviews total world Non-invasive DNA Prenatal Testing sales in 2023, providing a comprehensive analysis by region and market sector of projected Non-invasive DNA Prenatal Testing sales for 2024 through 2030. With Non-invasive DNA Prenatal Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-invasive DNA Prenatal Testing industry.

This Insight Report provides a comprehensive analysis of the global Non-invasive DNA Prenatal Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-invasive DNA Prenatal Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-invasive DNA Prenatal Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-invasive DNA Prenatal Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-invasive DNA Prenatal Testing.

United States market for Non-invasive DNA Prenatal Testing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Non-invasive DNA Prenatal Testing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Non-invasive DNA Prenatal Testing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Non-invasive DNA Prenatal Testing players cover Illumina, Roche, Natera, Thermo Fisher Scientific and F. Hoffman-La Roche, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Non-invasive DNA Prenatal Testing market by product type, application, key players and key regions and countries.

Segmentation by type
Equipment
Consumables

Segmentation by application
Hospital
Clinic
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Illumina
Roche
Natera
Thermo Fisher Scientific
F. Hoffman-La Roche
Pacific Biosciences Of California
Perkinelmer
LifeCodexx
Agilent Technologies
Labcorp
Mutiplicon
Premaitha Health
Beijing BGI
Berry Genomics
Darui Biological

Please note: The report will take approximately 2 business days to prepare and deliver.